Terry Chrisomalis | TalkMarkets | Page 1

Terry Chrisomalis

Contributor's Links: Biotechpicklist SeekingAlpha
I am a graduate of Business Administration and have created my own Pharmaceutical website "BiotechPicklist.com". I have been investing and writing about biotechnology stocks for 5 years now and have extensive experience writing about the science and companies themselves. I am a Seeking ...more
Following: 31 Followers: 123

Articles

Latest Posts
1 to 16 of 55 Posts
1 2 3 4 >>>
Shares Of Prosensa Surge 50% After Announcing It Will Be Acquired By Biomarin
Monday, November 24, 2014 10:33 AM EDT
Biomarin is purchasing Prosensa for approximately $840 million.
In this article: BMRN, RNA, SRPT, RGLS
Read
Merrimack Receives Fast Track For Pancreatic Cancer Drug
Wednesday, November 19, 2014 4:29 PM EDT
The reason the FDA gave MACK Fast Track approval is because there are no current therapies for pancreatic cancer -- the drug meets an unmet medical need.
In this article: BAX, MACK
Read
CytRx Announces Partial Clinical Hold On Main Drug' Big Buying Opportunity For Investors
Tuesday, November 18, 2014 2:36 PM EDT
Aldoxorubicin receives a partial clinical hold from the FDA.
In this article: CYTR
Read
Celldex Therapeutics Surges 30% After Positive Phase 2 Data In Brain Cancer
Monday, November 17, 2014 5:41 PM EDT
Positive results in an interim phase 2 analysis of rindopepimut show increased survival.
In this article: CLDX
Read
Inovio Discloses Deal Break-up Over Prostate Cancer Deal - Roche To Still Collaborate On Hepatitis B Vaccine
Monday, November 17, 2014 1:24 PM EDT
Inovio Pharmaceuticals Tumbles After Roche Deal Falls Apart On Prostate Cancer Vaccine Deal
In this article: JNJ, INO, RHHBY, MDVN
Read
Geron Closes Deal On Blood Cancer Drug With J&J
Friday, November 14, 2014 3:52 PM EDT
JNJ's Jansen Biotech enters deal to collaborate on Imetelstat.
In this article: JNJ, GERN
Read
Rxi Pharmaceuticals Offers Great Risk-Reward Scenario Before Major Catalysts
Friday, November 14, 2014 11:05 AM EDT
Rxi Pharmaceuticals is extremely undervalued should approaching catalysts fulfill promise.
In this article: TKMR, RXII, RGLS
Read
Dynavax May Offer An Opportunity In The Hepatitis B Space
Thursday, November 13, 2014 5:35 PM EDT
Dynavax's Hepatitis B vaccine Hepislav has the opportunity to bounce back; a first review is positive but there is a ways to go.
In this article: DVAX
Read
Achillion Pharmaceuticals Continues To Impress With Hepatitis C Results In A Combination Study
Tuesday, November 11, 2014 10:55 AM EDT
ACH-3102 showed 100% Hepatitis C virus clearance in combination with Gilead's sofosbuvir.
In this article: ACHN, GILD
Read
Dendreon Files For Bankruptcy, Stock Tanks
Monday, November 10, 2014 6:47 PM EDT
Dendreon files for Chapter 11 bankruptcy after disappointing sales for Provenge
In this article: JNJ, DNDN, MDVN
Read
Shares Of Intercept Pharmaceuticals Tumble 20% After NASH Data Posted Shows Safety Concerns
Friday, November 7, 2014 11:31 AM EDT
Two major problems are reported that mean a significant setback for Intercept's lead OCA drug.
In this article: ICPT
Read
Aeterna Zentaris Receives CRL From FDA For Adult Growth Hormone Deficiency Test
Thursday, November 6, 2014 7:02 PM EDT
FDA sends AEZS back to the drawing board with Macrilen.
In this article: AEZS
Read
Geron Shares Surge 25% After The Removal Of A Clinical Hold By The FDA
Tuesday, November 4, 2014 10:42 AM EDT
Imetelstat, a key blood cancer drug, is taken off FDA hold and can proceed to trial.
In this article: GERN
Read
Bristol-Myers Immunotherapy Drug Impresses With Phase 2 Lung Cancer Data
Thursday, October 30, 2014 8:22 PM EDT
Bristol-Myers posts outstanding results In lung cancer data using immunotherapy drug
In this article: BMY
Read
Sarepta Therapeutics Tumbles 30% After Delay Of Eteplirsen Approval
Monday, October 27, 2014 5:17 PM EDT
Though results were positive, FDA determines that eteplirsen study was too small and asks for more data.
In this article: SRPT
Read
Regulus Therapeutics Continues Its Uptrend After Positive Data In Early Hepatitis C Study
Friday, October 24, 2014 2:19 PM EDT
Shares of Regulus Therapeutics (RGLS) soared as much as 100% in one trading session after the company released some early data for their Hepatitis C drug.
In this article: RGLS
Read
1 to 16 of 55 Posts
1 2 3 4 >>>